REV ALERT: Faruqi & Faruqi, LLP Encourages Investors Who

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
98
REV ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In REV Group, Inc. To Contact The Firm

NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in REV Group, Inc. (“REV” or the “Company”) (NYSE: REVG ) of the August 7, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in REV securities on or about January 27, 2017 and would like to discuss your legal rights, click here : www.faruqilaw.com/REVG.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26 th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased REV securities pursuant and/or traceable to the Company’s Initial Public Offering (the “IPO”) on January 27, 2017. The case, Seth Marinoff v. REV Group, Inc. et al. , No. 18-cv-05095 was filed on June 8, 2018, and has been assigned to Judge S. James Otero.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose operational issues in its facilities as well as plan management within its IPO’s registration statement. The Company had touted that its vehicle backlog allowed it to predict future net sales and production needs.

Specifically, on June 6, 2018, REV reported its second quarter 2018 results for the period ended April 30, 2018, claiming that its earnings were “adversely impacted by near term commodity price inflation, supply chain constraints and shortfalls in [their] Commercial Segment.”

After the announcement, REV’s share price fell from $17.91 per share on June 6, 2018 to a closing price of $14.52 on June 7, 2018—a $3.39 or a 18.9% drop. Additionally, this closing price was approximately 34% below its $22 per share IPO price.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding REV’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Arkestro Recognized as Leading Sourcing Tech Solution in 2024

Updated Category News Views 138

Arkestro Celebrated as a Leading Sourcing Technology Provider Arkestro's innovative Predictive Procurement Orchestration AI platform has been recognized among the top contenders in the industry. This recognition comes as part of Spend Matters' release of their Fall 2024 SolutionMap, which acknowledges the leading procurement technology vendors. Out of 93 companies...

Continue Reading
Nanoscope Therapeutics Welcomes Ademola Daramola as VP of Quality

Updated Category News Views 178

Nanoscope Therapeutics Expands Leadership Team Nanoscope Therapeutics Inc., a dedicated biotechnology firm, strives to restore vision for blind patients through pioneering gene therapies. The company has recently appointed Ademola Daramola, D.Sc., as the Vice President of Quality and Compliance. Introducing Dr. Ademola Daramola Dr. Daramola joins Nanoscope with an...

Continue Reading
Lumentum Holdings Readies for Earnings Report with Optimism

Updated Category News Views 220

Lumentum Holdings Prepares for Earnings Release Lumentum Holdings (NASDAQ: LITE) is set to announce its quarterly earnings soon. Investors are eager to see what insights will emerge from the report, as expectations build around the company's performance. Investor Expectations and Earnings Forecast Analysts predict that Lumentum Holdings will post an earnings per share...

Continue Reading
LightPath Technologies Launches Infrared Solutions for Defense

Updated Category News Views 130

LightPath Technologies Initiates Delivery of Infrared Assemblies FPV Drone Infrared Lens Assemblies for European Defense Customer Expected to Drive $1.0-2.0 Million in Revenue in Calendar Year 2025 LightPath Technologies, Inc. (NASDAQ: LPTH), renowned for its advanced optics and imaging systems targeted at both defense and commercial utilizations, has announced that it...

Continue Reading
The RealReal Boosts Revenue and Adjusted EBITDA in Q3 2024

Updated Category News Views 57

Strong Q3 2024 Performance for The RealReal The RealReal (NASDAQ: REAL), a leader in the online marketplace for authenticated, resale luxury goods, reported significant financial gains in the third quarter of 2024. The company achieved a revenue of $148 million, which represents an increase of $15 million or 11% compared to the previous year. Notably, they also saw...

Continue Reading